Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Evan, Popoff"'
Autor:
Karissa Johnston, Linda Harris, Lauren Powell, Evan Popoff, Vladimir Coric, Gilbert L’Italien, Curtis P. Schreiber
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg
Externí odkaz:
https://doaj.org/article/ca75a2ff515142a39cb65087dd7b264a
Autor:
Gilbert L’Italien, Evan Popoff, Karissa Johnston, Donnie McGrath, Charles M Conway, Lauren Powell, Linda Harris, Nicole Kowalczyk, Robert Croop, Vladimir Coric
Publikováno v:
Cephalalgia Reports, Vol 5 (2022)
Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg a
Externí odkaz:
https://doaj.org/article/d3138efbe223411389222aae5a2240a0
Autor:
Lauren C. Powell, Gilbert L’Italien, Evan Popoff, Karissa Johnston, Fiona O’Sullivan, Linda Harris, Robert Croop, Vladimir Coric, Richard B. Lipton
Publikováno v:
Advances in Therapy. 40:585-600
Autor:
Karissa M, Johnston, Lauren, Powell, Evan, Popoff, Linda, Harris, Robert, Croop, Vladimir, Coric, Gilbert, L'Italien
Publikováno v:
The Clinical Journal of Pain. 38:680-685
To develop and compare benefit-risk profiles for rimegepant, ubrogepant, and lasmiditan based on a network meta-analysis (NMA) of published clinical trials.A fixed-effects Bayesian NMA of randomized controlled trials of lasmiditan, rimegepant, and ub
Publikováno v:
Journal of Medical Economics. 25:249-259
This study compared the aggregate duration of treatment administration of approved eculizumab and ravulizumab treatment regimens and resultant productivity implications for patients with atypical hemolytic uremic syndrome (aHUS) and their caregivers.
Autor:
Christina Qian, Shelagh M. Szabo, Katherine Gooch, Alexa Klimchak, Susan T. Iannaccone, Evan Popoff
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1426-1437
BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe X-linked progressive neurodegenerative disease characterized by loss of ambulation, cardiomyopathy, respiratory insufficiency, and early mo...
Publikováno v:
Health Information & Libraries Journal.
Given the increasing volume of published research in bibliographic databases, efficient retrieval of evidence is crucial and represents an opportunity to integrate novel techniques such as text mining.To develop and validate a geographic search filte
Autor:
Shelagh M. Szabo, Alexa C. Klimchak, Christina Qian, Susan Iannaccone, Evan Popoff, Katherine L. Gooch
Publikováno v:
Journal of neuromuscular diseases. 9(6)
Background: Data on the clinical course of Duchenne muscular dystrophy (DMD) exist from well-characterized clinical cohorts but estimates from real-world populations are fewer. Objective: The objective was to estimate the prevalence of key clinical m
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
Autor:
Vladimir Coric, Gilbert L'Italien, Robert Croop, Richard B. Lipton, Alexandra Thiry, Linda Harris, Evan Popoff, Lauren Powell, Karissa Johnston
Publikováno v:
Advances in Therapy
Introduction Migraine is a debilitating neurological condition, affecting up to 15% of Americans. Recent estimates from a long-term safety study of rimegepant showed evidence of decreased monthly migraine days (MMD) in people with episodic migraine t
Autor:
Alexandra Thiry, Gilbert L'Italien, Vladimir Coric, Robert Croop, James Moren, Linda Harris, Alison Deighton, Karissa Johnston, Evan Popoff, Parisa Dabirvaziri
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:155-166
Objective In the absence of head-to-head comparisons, the objective of this study was to conduct a network meta-analysis (NMA) to indirectly compare the relative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for the acute treatment of